An interventional study of Atropine and auricular acupoint stimulation in Myopia, sponsored by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation. Completed at 1 site in Taiwan. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2014-02-05.
Sponsored by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Not applicable, Interventional, and Treatment
To compare the effect of myopia control between patients treated with low-concentration atropine eye drops combined with auricular acupoint stimulation and those treated with atropine alone.
Myopia has been an increasing problem among school children, especially in Asian countries. High myopia is not only a refractive problem, but also a disease that can result in a number of sight-threatening complications such as macular degeneration, retinal detachment, glaucoma, and cataract. Atropine is a long-acting non-selective muscarinic antagonist that blocks accommodation by paralyzing ciliary muscles; it may affect remodeling of the sclera and suppress the elongation of axial length. Acupuncture and acupressure have been widely used in traditional Chinese medicine for thousands of years. Auricular acupoint stimulation by acupuncture or acupressure has been reported to improve visual acuity in myopic patients. Therefore, we want to compare the effect of myopia control between patients treated with low-concentration atropine eye drops combined with auricular acupoint stimulation and those who treated with atropine alone.
984 studies on the registry are indexed under Myopia; 210 are open to participants now.
This study's enrollment of 73 is close to the median of 80 across 783 interventional studies indexed under Myopia.
Browse Myopia studies →Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation is the lead sponsor of 55 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Five auricular acupoints were selected for taping stimulation by using a 1-mm alloy ball by fingers three times a day, each time for five minutes over the five selected acupoints. Topical 0.125% atropine was given nightly.
Drug: Atropine · Device: auricular acupoint stimulation
topical 0.125% atropine was given nightly during the study period.
Drug: Atropine
topical 0.125% atropine eye drops
Also known as: 0.125% atropine (Sinphar Pharmaceutical, Ilan, Taiwan)
Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
Also known as: a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan)
the change in spherical equivalent (SE)
We measured the myopic progression (change in SE) of all the participants for at least six months.
Time frame: SE measured at 3, 6, 9, 12 months.
axial length (AL) elongation, anterior chamber depth (ACD) and intraocular pressure(IOP)
We measured the axial length (AL) elongation, anterior chamber depth (ACD) and intraocular pressure(IOP) of all the participants for at least six months.
Time frame: AL, ACD, and IOP measure at 3, 6, 9, 12 months
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation